|
Name |
Quinolactacin A1
|
Molecular Formula | C16H18N2O2 | |
IUPAC Name* |
(3R)-3-[(2S)-butan-2-yl]-4-methyl-2,3-dihydropyrrolo[3,4-b]quinoline-1,9-dione
|
|
SMILES |
CC[C@H](C)[C@@H]1C2=C(C(=O)C3=CC=CC=C3N2C)C(=O)N1
|
|
InChI |
InChI=1S/C16H18N2O2/c1-4-9(2)13-14-12(16(20)17-13)15(19)10-7-5-6-8-11(10)18(14)3/h5-9,13H,4H2,1-3H3,(H,17,20)/t9-,13+/m0/s1
|
|
InChIKey |
FLHQAMWKNPOTDV-TVQRCGJNSA-N
|
|
Synonyms |
Quinolactacin A1; (+)-Quinolactacin A1; 815576-68-2; (3R)-2,3-dihydro-4-methyl-3-[(1S)-1-methylpropyl]-1H-pyrrolo[3,4-b]quinoline-1,9(4H)-dione; HY-N7480A; ZINC14684867; CS-0136107; (3R)-3-[(2S)-butan-2-yl]-4-methyl-2,3-dihydropyrrolo[3,4-b]quinoline-1,9-dione
|
|
CAS | NA | |
PubChem CID | 26202199 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 270.33 | ALogp: | 2.5 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 49.4 | Aromatic Rings: | 3 |
Heavy Atoms: | 20 | QED Weighted: | 0.911 |
Caco-2 Permeability: | -4.741 | MDCK Permeability: | 0.00001850 |
Pgp-inhibitor: | 0.049 | Pgp-substrate: | 0.879 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.112 |
Blood-Brain-Barrier Penetration (BBB): | 0.946 | Plasma Protein Binding (PPB): | 80.68% |
Volume Distribution (VD): | 1.469 | Fu: | 10.49% |
CYP1A2-inhibitor: | 0.918 | CYP1A2-substrate: | 0.824 |
CYP2C19-inhibitor: | 0.411 | CYP2C19-substrate: | 0.809 |
CYP2C9-inhibitor: | 0.497 | CYP2C9-substrate: | 0.534 |
CYP2D6-inhibitor: | 0.173 | CYP2D6-substrate: | 0.276 |
CYP3A4-inhibitor: | 0.531 | CYP3A4-substrate: | 0.212 |
Clearance (CL): | 2.275 | Half-life (T1/2): | 0.115 |
hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.217 |
Drug-inuced Liver Injury (DILI): | 0.251 | AMES Toxicity: | 0.872 |
Rat Oral Acute Toxicity: | 0.158 | Maximum Recommended Daily Dose: | 0.8 |
Skin Sensitization: | 0.087 | Carcinogencity: | 0.889 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.196 |
Respiratory Toxicity: | 0.352 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002158 | 0.522 | D06GKN | 0.356 | ||||
ENC004684 | 0.430 | D0K7WK | 0.356 | ||||
ENC004688 | 0.425 | D05EPM | 0.329 | ||||
ENC004691 | 0.425 | D07RGW | 0.320 | ||||
ENC004686 | 0.423 | D08UMH | 0.316 | ||||
ENC004693 | 0.423 | D0J6WW | 0.295 | ||||
ENC004267 | 0.389 | D06IXT | 0.295 | ||||
ENC002809 | 0.379 | D06BYV | 0.288 | ||||
ENC005470 | 0.368 | D03GET | 0.282 | ||||
ENC005998 | 0.360 | D08EOD | 0.280 |